Los Angeles Capital Management LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Los Angeles Capital Management LLC lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 2,625.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,700 shares of the biotechnology company’s stock after acquiring an additional 319,528 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.21% of Ironwood Pharmaceuticals worth $1,469,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IRWD. Pacer Advisors Inc. grew its position in Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after purchasing an additional 450,949 shares in the last quarter. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after buying an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 23.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after acquiring an additional 364,841 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of Ironwood Pharmaceuticals by 1,982.8% during the third quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock valued at $4,120,000 after acquiring an additional 951,988 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Ironwood Pharmaceuticals by 7.2% during the fourth quarter. Bank of New York Mellon Corp now owns 978,135 shares of the biotechnology company’s stock worth $4,333,000 after acquiring an additional 65,357 shares during the period.

Insider Activity

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 192,381 shares of company stock valued at $338,591 over the last quarter. Company insiders own 12.90% of the company’s stock.

Wall Street Analysts Forecast Growth

IRWD has been the topic of several research analyst reports. StockNews.com cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Craig Hallum reduced their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Finally, JMP Securities decreased their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.60.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $1.61 on Friday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $1.55 and a 1 year high of $11.00. The stock’s fifty day moving average price is $3.16 and its two-hundred day moving average price is $3.84. The firm has a market cap of $257.65 million, a PE ratio of -53.67 and a beta of 0.29.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.